We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.

(±)-CP 55,940

Item № 13241
CAS № 83003-12-7
Purity ≥98%
product image
                (CAS 83003-12-7)
     5 mg $65.00 0.00
     10 mg $124.00 0.00
     25 mg $293.00 0.00
     50 mg $520.00 0.00

Pricing updated 2019-03-26. Prices are subject to change without notice.


(±)-CP 55,940 is a potent, non-selective cannabinoid (CB) receptor agonist (Kis = 5 and 1.8 nM for human CB1 and CB2, respectively).1 It stimulates [35S]GTPγS binding to rat cerebellar membranes (EC50s = 0.22-0.96 nM).2 In vivo, (±)-CP 55,940 induces analgesia in the tail clamp, hot plate, tail flick, flinch jump, and PBQ-induced writhing tests with 50% maximum possible effect (MPE50) values of 0.46, 1.11, 0.55, 0.63, and 0.29 mg/kg, respectively.3 (±)-CP 55,940 also decreases the discrimination index (DI) of female, but not male, rats in the object location task as well as the DI of male, but not female, rats in the novel object recognition task.4

Recommended Products

Related Products
View Related Product Categories
View Screening Libraries with (±)-CP 55,940
Technical Information
Formal Name
CAS Number
Molecular Formula
Formula Weight
A crystalline solid
278 nm
InChI Code
InChI Key

Warning - this product is not for human or veterinary use.

Shipping & Storage
Room temperature in continental US; may vary elsewhere
≥ 2 years
Downloads & Resources
Product Downloads

Download Product Insert

Download GC-MS

Download Safety Data Sheet (SDS)

Download free InChI Key generation software

Additional Information

View the Cayman Structure Database for chemical structure definitions for many Cayman products

Get Batch-Specific Data and Documents by Batch Number

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.

References & Product Citations
Product Description References

1. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands Curr. Med. Chem. 6(8), 635-664 (1999).

2. Griffin, G., Atkinson, P.J., Showalter, V.M., et al. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes J. Pharmacol. Exp. Ther. 285(2), 553-560 (1998).

3. Howlett, A.C., Johnson, M.R., Melvin, L.S., et al. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model Mol. Pharmacol. 33(3), 297-302 (1987).

4. Mateos, B., Borcel, E., Loriga, R., et al. Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB1 cannabinoid receptors J. Psychopharmacol. 25(12), 1676-1690 (2011).

Product Citations

Ciolino, L.A. Quantitation of synthetic cannabinoids in plant materials using high performance liquid chromatography with UV detection (validated method) J.Forensic Sci. 60(5), 1171-1181 (2015).

Technical Support
Contact Us
  • Toll Free Phone (USA and Canada Only): (888) 526-5351
  • Direct Phone: (734) 975-3888
Cayman Contract Services

We work with scientists to accelerate their research, drug discovery, and drug development needs through our expertise in the following areas:

Cayman Chemical

1180 East Ellsworth Road

Ann Arbor, Michigan 48108 USA

Toll Free: (800) 364-9897

(USA and Canada Only)

Fax: (734) 971-3640